Medicine and Dentistry
Non Small Cell Lung Cancer
77%
Randomized Controlled Trial
68%
Quality Adjusted Life Year
63%
Health Care Cost
61%
Cost-Effectiveness Analysis
59%
Placebo
51%
Physical Activity
44%
Cognitive Defect
44%
Paclitaxel
44%
Quality of Life
35%
Diseases
33%
Lung Cancer
32%
Noninvasive Ventilation
32%
Health Status
29%
Artificial Respiration
25%
Ventilator Weaning
24%
Intensive Care
24%
Malignant Neoplasm
22%
Mandibular Third Molar
22%
B-Cell Chronic Lymphocytic Leukemia
22%
Molar Tooth
22%
Erlotinib
22%
Oncolytic Adenovirus
22%
Dental Caries
22%
Saracatinib
22%
Primary Peritoneal Cancer
22%
Cell Therapy
22%
Coxsackie Virus and Adenovirus Receptor
22%
Cell Cycle Regulation
22%
Receptor Expression
22%
Extubation
22%
Minimal Residual Disease
22%
Hypofractionated Radiotherapy
22%
Fallopian Tube
22%
Allogeneic Hematopoietic Stem Cell Transplantation
22%
Effect Size
22%
Cediranib
22%
Gefitinib
22%
Glioblastoma
22%
Phase II Trials
22%
Arm Exercise
19%
Odds Ratio
18%
Arm
17%
Overall Survival
17%
Graft Versus Host Reaction
16%
Donor Lymphocyte Infusion
16%
Radiation Therapy
16%
Exanthem
14%
Supportive Care
14%
Neoplasm
14%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Chemotherapy
68%
Placebo
51%
Cediranib
44%
Glioblastoma
44%
Gefitinib
44%
Neoplasm
42%
Clinical Trial
35%
Health Status
29%
Lung Cancer
27%
Myeloma
22%
Phase II Trials
22%
Bortezomib
22%
Erlotinib
22%
Antibiotics
22%
Oncolytic Adenovirus
22%
Respiratory Tract Infection
22%
Randomized Controlled Trial
22%
Paclitaxel
22%
Coxsackie Virus and Adenovirus Receptor
22%
Overall Survival
21%
Malignant Neoplasm
16%
Chemoradiation Therapy
15%
Rash
14%
Vinorelbine
14%
Cisplatin
14%
Progression Free Survival
12%
Maximum Tolerated Dose
9%
Ovary Cancer
9%
Esophagitis
8%
Tolerability
8%
Neurotoxicity
7%
Mixture Model
7%
Disease Exacerbation
7%
Cross-Validation
7%
Phase III Trials
6%
Survival Rate
6%
Adenoviridae
5%
N (4 Methoxyphenylacetyl)dehydroalanine
5%
Nursing and Health Professions
Cost Effectiveness Analysis
57%
Cognitive Defect
44%
Quality Adjusted Life Year
41%
Quality of Life
35%
Noninvasive Ventilation
32%
Artificial Respiration
25%
Confidence Interval
24%
Intensive Care
24%
Ventilator Weaning
24%
Erlotinib
22%
Malignant Neoplasm
22%
Effect Size
22%
Extubation
22%
Non Small Cell Lung Cancer
22%
Arm Exercise
19%
Odds Ratio
17%
Rash
14%
Economic Evaluation
13%
Alzheimer's Disease
11%
Alzheimer Disease Assessment Scale
11%
Socialized Medicine
10%
Clinical Outcome
8%
Respiratory Tract Infection
7%
Disease Exacerbation
7%
Placebo
7%
Disease Assessment
6%
Obstructive Lung Disease
5%
Walking Distance
5%
Six Minute Walk Test
5%
Randomization
5%
Compliance
5%
Primary Medical Care
5%
